Taylor Teague
Clinical Genetics (M.D.) · Tyler, TXNPI 1578983128
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,006 of the $4,306 with a category attached, or 69.8%. 24 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 50.0% of the total. Reporting peaked in 2022 at $2,064 and has fallen 66.6% since, to $689 in 2025.
Across 119 payments — averaging $36.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- Jazz Pharmaceuticals Inc.$443
- GSK$367
- Harmony Biosciences LLC$362
- Sanofi$149
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$118
- plus $713 from 18 others
What the payments were for
- Travel & lodging$1,05524%
- Food & beverage$3,00670%
- Education$2456%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 6 | $2,153 |
| Jazz Pharmaceuticals Inc. | 12 | $443 |
| GSK | 35 | $367 |
| Harmony Biosciences LLC | 17 | $362 |
| Sanofi | 6 | $149 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $118 |
| Electromed, Inc. | 6 | $89 |
| United Therapeutics Corporation | 4 | $85 |
| AstraZeneca | 5 | $80 |
| Boehringer Ingelheim | 4 | $80 |
| ANI Pharmaceuticals, Inc. | 3 | $65 |
| Axsome Therapeutics, Inc. | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| Mylan Specialty L.p. | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Viatris Specialty LLC | 1 | $24 |
| Grifols USA, LLC | 1 | $19 |
| Pharming Healthcare, Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Inogen, Inc. | 3 | $16 |
| Philips North America LLC | 1 | $12 |
| 3b Medical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire Upper Airway Stimulation System$1,897
- Inspire$131
- SUNOSI$125
How this compares
$4,306 in reported general payments places this provider in the 70th percentile of 37 clinical genetics (m.d.) providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $17,220 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $10,143 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $8,623 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $4,738 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 33 | $1,676 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,271 |
| Montelukast Sodium | 12 | $75 |
| Azithromycin | 14 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $367 | $32,10154 claims |
| Boehringer IngelheimStiolto Respimat | $80 | $8,62318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 37 clinical genetics (m.d.) providers in Texas.
Other clinical genetics (m.d.) in Tyler
- Joseph GoldsteinDallas$5.5M
- Joseph RayGalveston$642K
- Markey McNuttDallas$247K
- Hope NorthrupHouston$180K
- Paul HillmanHouston$68K
- Erin CooneyLeague City$44K
- Brendan LeeHouston$28K
- David RodriguezHouston$28K
- Fernando ScagliaHouston$16K
- Candace GambleFort Worth$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.